Would you choose neoadjuvant endocrine therapy for a low grade, node negative, ER/PR positive, breast cancer given delays in definitive surgery due to the COVID-19 pandemic?  

Would your choice vary based on the patient's gender?



Answer from: Medical Oncologist at Academic Institution